KCT0003554尚未招募未知
A study of Daesiho-tang on weight loss in Obese Patients with non-alcoholic fatty liver disease: a double-blind, placebo-controlled randomized clinical trial
Dunsan Korean Medicine Hospital of Daejeon University0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 64(Year)（—）
- 性别
- All
入选标准
- •(1) Adults over 19 years to under 65 years
- •(2) Obese subjects with body mass index =25 kg/m2
- •(3) Subjects with non-alcoholic fatty liver findings on Fibroscan analysis: CAP (Controlled Attenuation Parameter) score over 268 dB/m
- •(4) Those who have voluntarily signed written consent approved by IRB, after sufficient explanation of this study
排除标准
- •(1) Subjects who have had weight changes more than 10% of their previous weight within the last 6 months
- •(2) Subjects who are already on diet or heavy exercise for weight control purposes
- •(3) Subjects who had undergone surgical procedures (such as gastroplasty) for weight control
- •(4) Patients with endocrine disease that may affect body weight, such as hypothyroidism, Cushing's syndrome, or those with TSH concentration less than 0.1 uU/ml or more than 10.0 uU/ml
- •(5) Patients with evidence of chronic hepatitis, such as hepatitis B, hepatitis C, autoimmune hepatitis, and metabolic hepatitis (HBsAg or HCV Ab positive in screening tests)
- •(6) Subjects with alcohol intake over 210 grams per week for men and over 140 grams for women during the last year
- •(7) Liver Stiffness Measurement (LSM) of 12.5 kPa or higher on FibroScan test
- •(8) Subjects who have received liver transplants
- •(9) Subjects who use insulin injections to control blood glucose concentration
- •(10) Subjects taking thiazolidinediones and high-dose vitamin E that may affect non-alcoholic fatty liver disease
- •(11) Those who had taken drugs that can be used to treat obesity (absorption inhibitors and appetite suppressants), antidepressants, contraceptives, oral steroids, amphetamines, phenodiazines, ciproheptadins, female hormones or thyroid hormones within 3 months of screening
- •(12) Those whose AST or ALT exceeds 5 times the normal upper limit (200 IU/L)
- •(13) Kidney dialysis patients or those with creatinine concentration more than twice the normal upper limit
- •(14) Those who are in seriously unstable medical conditions such as cardiovascular disease, respiratory disease, gastrointestinal disease, hepatobiliary disease, metabolic disease, endocrine disease, renal disease or problems in urinary reproductive system and nervous system
- •(15) Those who have had diagnosed or have been treated for malignant tumors within the last 5 years
- •(16) Women who are pregnant or lactating, or subjects who do not agree to use effective methods of contraception during the clinical trial (Oral contraceptives are not allowed during the clinical trial)
- •(17) Subjects with genetic problems, such as galactose intolerance, Lapp lactase deficiency, or glucose-galatose malabsroption
- •(18) Subjects with a history of alcohol abuse or drug abuse within the past year
- •(19) Subjects who had taken other clinical trial drugs within 3 months
- •(20) Subjects who are thought to be inappropriate for this study
研究者
相似试验
尚未招募
不适用
Anti-obesity effect of Bangpungtongseong-san and Daeshiho-tang: Randomized, Double blind clinical trialKCT0006600Dongguk University Ilsan Oriental Hospital146
尚未招募
不适用
The usefulness of body weight loss program in patients with cancerThe obesity patients with gastric cancer and colon cancerJPRN-UMIN000026284Tokushima University30
尚未招募
Unknown
Investigation on the anti-obesity effects of research food intakeJPRN-UMIN000054009Metagen, Inc.20
已完成
不适用
Investigating the effects of the herbal medicine Taeeumjowui-tang on obesity and metabolic syndrome risk factorsISRCTN13677132Cheonan Oriental Hospital of Daejeon University206
招募中
不适用
The effect of DASH diet on NAFLDon-alcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classifiedK76.0IRCT20100209003320N19Tabriz University of Medical Sciences44